TD-0903
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- TD-0903
- DrugBank Accession Number
- DB16463
- Background
TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 527.673
Monoisotopic: 527.300873459 - Chemical Formula
- C30H37N7O2
- Synonyms
- (3-(DIMETHYLAMINO)AZETIDIN-1-YL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-(PROPAN-2-YL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE
- (S)-(3-(DIMETHYLAMINO)AZETIDIN-1-YL)(2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-ISOPROPYL-4,5,6,7-TETRAHYDRO-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE
- METHANONE, (3-(DIMETHYLAMINO)-1-AZETIDINYL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-4,5,6,7-TETRAHYDRO-5-(1-METHYLETHYL)-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)-
- NEZULCITINIB
- External IDs
- TD-0903
- THRX-136377
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
TD-0903 is a nebulized inhalation solution that inhibits janus kinase and selectively targets the lungs. This inhibition of JAK-STAT signalling aims to reduce complications associated with cytokine challenges in the airways. The anti-inflammatory mechanism associated with TD-0903 may reduce hyperinflammation in patients experiencing acute respiratory distress syndrome (ARDS).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- CXA4I8AH6A
- CAS number
- 2412496-23-0
- InChI Key
- VQIIUJSNIKEMCK-MHZLTWQESA-N
- InChI
- InChI=1S/C30H37N7O2/c1-6-18-11-21(38)8-10-22(18)19-7-9-23-24(12-19)33-34-28(23)29-31-25-13-27(37(17(2)3)16-26(25)32-29)30(39)36-14-20(15-36)35(4)5/h7-12,17,20,27,38H,6,13-16H2,1-5H3,(H,31,32)(H,33,34)/t27-/m0/s1
- IUPAC Name
- SMILES
- CCC1=C(C=CC(O)=C1)C1=CC=C2C(NN=C2C2=NC3=C(C[C@H](N(C3)C(C)C)C(=O)N3CC(C3)N(C)C)N2)=C1
References
- General References
- External Links
- ChemSpider
- 115009351
- ChEMBL
- CHEMBL4802163
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Acute Lung Injury (ALI) Associated With COVID-19 / Coronavirus Disease 2019 (COVID‑19) / Lung Inflammation Associated With COVID-19 1 somestatus stop reason just information to hide 1 Completed Treatment Acute Lung Injury (ALI) Associated With COVID-19 / Coronavirus Disease 2019 (COVID‑19) / Inflammatory Lung Conditions Associated With COVID-19 1 somestatus stop reason just information to hide 1 Completed Treatment Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 21, 2021 01:43 / Updated at July 24, 2024 23:35